7 results on '"Bétrisey, Sylvain"'
Search Results
2. Lipid‐Lowering Therapy and Risk of Hemorrhagic Stroke: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
- Author
-
Bétrisey, Sylvain, primary, Haller, Moa Lina, additional, Efthimiou, Orestis, additional, Speierer, Alexandre, additional, Del Giovane, Cinzia, additional, Moutzouri, Elisavet, additional, Blum, Manuel R., additional, Aujesky, Drahomir, additional, Rodondi, Nicolas, additional, and Gencer, Baris, additional
- Published
- 2024
- Full Text
- View/download PDF
3. Is there a shift from cardiovascular to cancer death in lipid-lowering trials? A systematic review and meta-analysis
- Author
-
Bolt, Lucy, primary, Speierer, Alexandre, additional, Bétrisey, Sylvain, additional, Aeschbacher-Germann, Martina, additional, Blum, Manuel R., additional, Gencer, Baris, additional, Del Giovane, Cinzia, additional, Aujseky, Drahomir, additional, Moutzouri, Elisavet, additional, and Rodondi, Nicolas, additional
- Published
- 2024
- Full Text
- View/download PDF
4. Association of statin use and lipid levels with cerebral microbleeds and intracranial hemorrhage in patients with atrial fibrillation: A prospective cohort study
- Author
-
Moutzouri, Elisavet; https://orcid.org/0000-0002-7713-7553, Glutz, Matthias, Abolhassani, Nazanin, Feller, Martin; https://orcid.org/0000-0003-2519-836X, Adam, Luise, Gencer, Baris; https://orcid.org/0000-0002-8954-9694, Del Giovane, Cinzia, Bétrisey, Sylvain, Paladini, Rebecca E; https://orcid.org/0000-0002-4502-1978, Hennings, Elisa; https://orcid.org/0000-0003-2616-5535, Aeschbacher, Stefanie; https://orcid.org/0000-0001-8134-2421, Beer, Jürg H; https://orcid.org/0000-0002-7199-0406, Moschovitis, Giorgio; https://orcid.org/0000-0002-4043-8061, Seiffge, David, De Marchis, Gian Marco; https://orcid.org/0000-0002-0342-9780, Coslovsky, Michael; https://orcid.org/0000-0001-7678-7354, Reichlin, Tobias; https://orcid.org/0000-0002-7197-8415, Conte, Giulio, Sinnecker, Tim, Schwenkglenks, Matthias; https://orcid.org/0000-0001-7217-1173, Bonati, Leo H; https://orcid.org/0000-0003-1163-8133, Kastner, Peter, Aujesky, Drahomir; https://orcid.org/0000-0002-3970-2670, Kühne, Michael; https://orcid.org/0000-0002-2937-3711, Osswald, Stefan; https://orcid.org/0000-0002-9240-6731, Fischer, Urs; https://orcid.org/0000-0003-0521-4051, Conen, David; https://orcid.org/0000-0002-2459-5251, Rodondi, Nicolas; https://orcid.org/0000-0001-9083-6896, Moutzouri, Elisavet; https://orcid.org/0000-0002-7713-7553, Glutz, Matthias, Abolhassani, Nazanin, Feller, Martin; https://orcid.org/0000-0003-2519-836X, Adam, Luise, Gencer, Baris; https://orcid.org/0000-0002-8954-9694, Del Giovane, Cinzia, Bétrisey, Sylvain, Paladini, Rebecca E; https://orcid.org/0000-0002-4502-1978, Hennings, Elisa; https://orcid.org/0000-0003-2616-5535, Aeschbacher, Stefanie; https://orcid.org/0000-0001-8134-2421, Beer, Jürg H; https://orcid.org/0000-0002-7199-0406, Moschovitis, Giorgio; https://orcid.org/0000-0002-4043-8061, Seiffge, David, De Marchis, Gian Marco; https://orcid.org/0000-0002-0342-9780, Coslovsky, Michael; https://orcid.org/0000-0001-7678-7354, Reichlin, Tobias; https://orcid.org/0000-0002-7197-8415, Conte, Giulio, Sinnecker, Tim, Schwenkglenks, Matthias; https://orcid.org/0000-0001-7217-1173, Bonati, Leo H; https://orcid.org/0000-0003-1163-8133, Kastner, Peter, Aujesky, Drahomir; https://orcid.org/0000-0002-3970-2670, Kühne, Michael; https://orcid.org/0000-0002-2937-3711, Osswald, Stefan; https://orcid.org/0000-0002-9240-6731, Fischer, Urs; https://orcid.org/0000-0003-0521-4051, Conen, David; https://orcid.org/0000-0002-2459-5251, and Rodondi, Nicolas; https://orcid.org/0000-0001-9083-6896
- Abstract
BACKGROUND An increased risk of intracranial hemorrhage (ICH) associated with statins has been reported, but data on the relationship between statin use and cerebral microbleeds (CMBs) in patients with atrial fibrillation (AF), a population at high bleeding and cardiovascular risk, are lacking. AIMS To explore the association between statin use and blood lipid levels with the prevalence and progression of CMBs in patients with AF with a particular focus on anticoagulated patients. METHODS Data of Swiss-AF, a prospective cohort of patients with established AF, were analyzed. Statin use was assessed during baseline and throughout follow-up. Lipid values were measured at baseline. CMBs were assessed using magnetic resonance imagining (MRI) at baseline and at 2 years follow-up. Imaging data were centrally assessed by blinded investigators. Associations of statin use and low-density lipoprotein (LDL) levels with CMB prevalence at baseline or CMB progression (at least one additional or new CMB on follow-up MRI at 2 years compared with baseline) were assessed using logistic regression models; the association with ICH was assessed using flexible parametric survival models. Models were adjusted for hypertension, smoking, body mass index, diabetes, stroke/transient ischemic attack, coronary heart disease, antiplatelet use, anticoagulant use, and education. RESULTS Of the 1693 patients with CMB data at baseline MRI (mean ± SD age 72.5 ± 8.4 years, 27.6% women, 90.1% on oral anticoagulants), 802 patients (47.4%) were statin users. The multivariable adjusted odds ratio (adjOR) for CMBs prevalence at baseline for statin users was 1.10 (95% CI = 0.83-1.45). AdjOR for 1 unit increase in LDL levels was 0.95 (95% CI = 0.82-1.10). At 2 years, 1188 patients had follow-up MRI. CMBs progression was observed in 44 (8.0%) statin users and 47 (7.4%) non-statin users. Of these patients, 64 (70.3%) developed a single new CMB, 14 (15.4%) developed 2 CMBs, and 13 developed more than 3 CMBs. The
- Published
- 2023
5. Association of statin use and lipid levels with cerebral microbleeds and intracranial hemorrhage in patients with atrial fibrillation: A prospective cohort study.
- Author
-
Moutzouri, Elisavet, Glutz, Matthias, Abolhassani, Nazanin, Feller, Martin, Adam, Luise, Gencer, Baris, Del Giovane, Cinzia, Bétrisey, Sylvain, Paladini, Rebecca E, Hennings, Elisa, Aeschbacher, Stefanie, Beer, Jürg H, Moschovitis, Giorgio, Seiffge, David, De Marchis, Gian Marco, Coslovsky, Michael, Reichlin, Tobias, Conte, Giulio, Sinnecker, Tim, and Schwenkglenks, Matthias
- Subjects
INTRACRANIAL hemorrhage ,STATINS (Cardiovascular agents) ,ATRIAL fibrillation ,TRANSIENT ischemic attack ,CORONARY disease - Abstract
Background: An increased risk of intracranial hemorrhage (ICH) associated with statins has been reported, but data on the relationship between statin use and cerebral microbleeds (CMBs) in patients with atrial fibrillation (AF), a population at high bleeding and cardiovascular risk, are lacking. Aims: To explore the association between statin use and blood lipid levels with the prevalence and progression of CMBs in patients with AF with a particular focus on anticoagulated patients. Methods: Data of Swiss-AF, a prospective cohort of patients with established AF, were analyzed. Statin use was assessed during baseline and throughout follow-up. Lipid values were measured at baseline. CMBs were assessed using magnetic resonance imagining (MRI) at baseline and at 2 years follow-up. Imaging data were centrally assessed by blinded investigators. Associations of statin use and low-density lipoprotein (LDL) levels with CMB prevalence at baseline or CMB progression (at least one additional or new CMB on follow-up MRI at 2 years compared with baseline) were assessed using logistic regression models; the association with ICH was assessed using flexible parametric survival models. Models were adjusted for hypertension, smoking, body mass index, diabetes, stroke/transient ischemic attack, coronary heart disease, antiplatelet use, anticoagulant use, and education. Results: Of the 1693 patients with CMB data at baseline MRI (mean ± SD age 72.5 ± 8.4 years, 27.6% women, 90.1% on oral anticoagulants), 802 patients (47.4%) were statin users. The multivariable adjusted odds ratio (adjOR) for CMBs prevalence at baseline for statin users was 1.10 (95% CI = 0.83–1.45). AdjOR for 1 unit increase in LDL levels was 0.95 (95% CI = 0.82–1.10). At 2 years, 1188 patients had follow-up MRI. CMBs progression was observed in 44 (8.0%) statin users and 47 (7.4%) non-statin users. Of these patients, 64 (70.3%) developed a single new CMB, 14 (15.4%) developed 2 CMBs, and 13 developed more than 3 CMBs. The multivariable adjOR for statin users was 1.09 (95% CI = 0.66–1.80). There was no association between LDL levels and CMB progression (adjOR 1.02, 95% CI = 0.79–1.32). At follow-up 14 (1.2%) statin users had ICH versus 16 (1.3%) non-users. The age and sex adjusted hazard ratio (adjHR) was 0.75 (95% CI = 0.36–1.55). The results remained robust in sensitivity analyses excluding participants without anticoagulants. Conclusions: In this prospective cohort of patients with AF, a population at increased hemorrhagic risk due to anticoagulation, the use of statins was not associated with an increased risk of CMBs. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. sj-docx-1-wso-10.1177_17474930231181010 – Supplemental material for Association of statin use and lipid levels with cerebral microbleeds and intracranial hemorrhage in patients with atrial fibrillation: A prospective cohort study
- Author
-
Moutzouri, Elisavet, Glutz, Matthias, Abolhassani, Nazanin, Feller, Martin, Adam, Luise, Gencer, Baris, Del Giovane, Cinzia, Bétrisey, Sylvain, Paladini, Rebecca E, Hennings, Elisa, Aeschbacher, Stefanie, Beer, Jürg H, Moschovitis, Giorgio, Seiffge, David, De Marchis, Gian Marco, Coslovsky, Michael, Reichlin, Tobias, Conte, Giulio, Sinnecker, Tim, Schwenkglenks, Matthias, Bonati, Leo H, Kastner, Peter, Aujesky, Drahomir, Kühne, Michael, Osswald, Stefan, Fischer, Urs, Conen, David, and Rodondi, Nicolas
- Subjects
FOS: Clinical medicine ,Cardiology ,Medicine ,110904 Neurology and Neuromuscular Diseases - Abstract
Supplemental material, sj-docx-1-wso-10.1177_17474930231181010 for Association of statin use and lipid levels with cerebral microbleeds and intracranial hemorrhage in patients with atrial fibrillation: A prospective cohort study by Elisavet Moutzouri, Matthias Glutz, Nazanin Abolhassani, Martin Feller, Luise Adam, Baris Gencer, Cinzia Del Giovane, Sylvain Bétrisey, Rebecca E Paladini, Elisa Hennings, Stefanie Aeschbacher, Jürg H Beer, Giorgio Moschovitis, David Seiffge, Gian Marco De Marchis, Michael Coslovsky, Tobias Reichlin, Giulio Conte, Tim Sinnecker, Matthias Schwenkglenks, Leo H Bonati, Peter Kastner, Drahomir Aujesky, Michael Kühne, Stefan Osswald, Urs Fischer, David Conen and Nicolas Rodondi in International Journal of Stroke
- Published
- 2023
- Full Text
- View/download PDF
7. Achilles tendon ultrasonography in the clinical screening of familial hypercholesterolaemia - a cross-sectional analysis.
- Author
-
De Montmollin M, Bétrisey S, Feller M, Moutzouri E, Blum MR, Amsler J, Papazoglou DD, Möller B, and Rodondi N
- Subjects
- Humans, Middle Aged, Cholesterol, LDL, Cross-Sectional Studies, Ultrasonography, Achilles Tendon diagnostic imaging, Cardiovascular Diseases, Hyperlipoproteinemia Type II diagnostic imaging
- Abstract
Background and Aims: People with familial hypercholesterolaemia are 13 times more likely to develop cardiovascular disease than the general population. However, familial hypercholesterolaemia remains largely underdiagnosed. Tendon xanthoma is a specific clinical feature of familial hypercholesterolaemia and its presence alone implies a probable diagnosis of familial hypercholesterolaemia according to the Dutch Lipid Clinic Network Score (DLCNS). The aim of the study was to determine whether ultrasound detects more Achilles tendon xanthomas (ATX) than clinical examination., Methods: We recruited 100 consecutive patients with LDL-C ≥4 mmol/l. Achilles tendons were evaluated through clinical examination by trained physicians and sonographic examination by another physician blind to the results of clinical examination. Blind second readings of ultrasound images were performed by an expert in musculoskeletal ultrasound. We compared the proportion of patients with ATX detected by either clinical examination or ultrasound and the proportion of patients with a probable/definite familial hypercholesterolaemia diagnosis on the DLCNS before and after ultrasound., Results: Mean (SD) age was 47 (12) years; mean highest LDL-C was 6.57 mmol/l (2.2). ATX were detected in 23% of patients by clinical examination and in 60% by ultrasound. In consequence, 43% had a probable/definite diagnosis of familial hypercholesterolaemia on the DLCNS using clinical examination compared with 72% when ultrasound was used., Conclusion: Compared to clinical examination, ultrasound examination of the Achilles tendon substantially improves the detection of ATX and may help to better identify patients with familial hypercholesterolaemia who are at high risk for premature cardiovascular disease.
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.